Sheeba Irshad is a CRUK clinician scientist (KCL) and breast cancer medical oncologist (GSTT). She has recently taken on the role as the clinical Deputy Head of the KCL Breast Cancer Now Unit responsible for the running of the breast cancer profiling translational research protocol. Her research group focusses on understanding the immune landscape of chemotherapy resistant disease. She is the translational lead and coordinating investigator for a clinical trial platform with biomarker endpoints (PHOENIX), which explores the potential interactions between DNA damage response inhibitors and immunotherapy in TNBC. More recently, she is the chief investigator of a multi-centre “SOAP” study: Sars-Cov-2 for Cancer Patients which aims to investigate the immune responses to COVID-19 in cancer patients.